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Abstract
Background: Plasmodium falciparum malaria remains a leading health problem in Africa and its control is seriously
challenged by drug resistance. Although resistance to the sulphadoxine-pyrimethamine (SP) is widespread, this
combination remains an important component of malaria control programmes as intermittent preventive therapy
(IPT) for pregnant women and children. In Angola, resistance patterns have been poorly characterized, and IPT has
been employed for pregnant women since 2006. The aim of this study was to assess the prevalence of key
antifolate resistance mediating polymorphisms in the pfdhfr and pfdhps genes in P. falciparum samples from
Angola.
Methods: Plasmodium falciparum samples collected in Luanda, in 2007, were genotyped by amplification and DNA
forward and reverse sequencing of the pfdhfr and pfdhps genes.
Results: The most prevalent polymorphisms identified were pfdhfr 108N (100%), 51I (93%), 59R (57%) and pfdhps
437G (93%). Resistance-mediating polymorphisms in pfdhps less commonly observed in West Africa were also
identified (540E in 10%, 581G in 7% of samples).
Conclusion: This study documents an important prevalence of 4 P. falciparum polymorphisms that predicts an
antifolate resistance in Luanda. Further, some samples presented additional mutations associated to high-level
resistance. These results suggest that the use of SP for IPT may no longer be warranted in Angola.
Background
Sub-Saharan countries remain affected by Plasmodium
falciparum malaria, with few exceptions. In 2009, there
were an estimated 225 million cases of malaria and
781,000 deaths from malaria worldwide, most of them
from Africa [1]. As in other parts of this continent,
malaria remains a major problem in Angola, where the
entire population is at risk of infection. In 2009,
3,726,606 suspected malaria cases were reported and
1,5734,222 malaria cases were confirmed by either RDT
or microscopy. The number of confirmed outpatient
cases remained nearly one million per year in the last
four years, whereas inpatient malaria cases and deaths
in 2009 decreased by about 31% and 13% respectively,
compared to the annual average in 2000-2005. However,
it is not clear from the available data whether this
reflects a true decrease [1].
The control of malaria is seriously challenged by drug
resistance. Resistance to the combination antifolate sul-
phadoxine-pyrimethamine (SP) is widespread, and this
drug is no longer recommended for therapy of falci-
parum malaria [2]. However, SP resistance is at an inter-
mediate level (e.g. parasite populations more tolerant to
the drug but still cleared by the treatment) in most of
Africa, and the drug remains an important component
of malaria control programmes for use as intermittent
preventive therapy (IPT) in pregnant women and chil-
dren [3]. IPT involves periodic administration of full
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parasitaemia [4]. IPT with SP has been efficacious in the
prevention of malaria in pregnant women [5] and chil-
dren [6], although protective regimens have not been
optimized, and the impact of different levels of SP resis-
tance on protective efficacy is not well understood [7].
Resistance to SP is mediated by point mutations in
genes encoding the target enzymes dihydrofolate reduc-
tase (pfdhfr) and dihydropteroate synthetase (pfdhps)
[8,9]. Increasing numbers of a well-defined set of muta-
tions leads to increasing resistance [10,11]. In Africa,
three pfdhfr (51I, 59R, 108N) and two pfdhps (437G,
540E) mutations are common in some areas, and the
prevalence of the key polymorphisms, pfdhfr 59R and
pfdhps 540E is associated with the treatment efficacy of
SP [12,13]. The treatment efficacy of SP in IPT remains
quite good in parts of west and central Africa, in large
part due to the lack of one key polymorphism, pfdhps
540E, in infecting parasites [14,15]. Considering differ-
e n c e si np r e v a l e n c eo ft h i sk e yp o l y m o r p h i s ma c r o s s
Africa and its importance, the WHO recommends IPT
with SP for infants only in areas with a prevalence of
pfdhps 540E < 50% [16]. Since IPT continues to be
recommended in pregnancy across Africa, the aim of
this study was to assess the prevalence of key antifolate
resistance mediating polymorphisms in the capital of
Angola, Luanda, where molecular resistance patterns
have not been characterized yet, and where SP for preg-
nancy has been employed since 2006 [17].
Methods
Study site and population
Blood samples were collected in 2007 from outpatients
attending for malaria diagnosis at four Luanda health
facility posts located at the municipalities of Sambi-
zanga, Imgombotas, Cazenga and Viana. Luanda has a
population of approximately 4.5 million and is consid-
ered mesoendemic for malaria. Malaria is present
throughout the year, with a marked increase in inci-
dence after rains that peak during April and May.
Patients diagnosed with falciparum malaria based on
Giemsa-stained thick smears were included in this study
after informed consent was obtained. Inclusion criteria
comprised individuals with age ≥ 12 years, no clinical
evidence of complicated malaria and monoinfection
with P. falciparum. The study was approved by the
National Institute of Public Health/Angola Ethics
Research Committee with agreement of the Instituto
Oswaldo Cruz/Fiocruz.
Study procedures
After enrollment, 5 ml of blood was collected by veni-
puncture and placed into ethylenediaminetetraacetic
acid vacutainer tubes (Becton Dickinson). The samples
were centrifuged (350 g, 10 minutes), and pellets were
frozen with an equal volume of cryopreservation solu-
tion (0.9% sodium chloride, 4.2% sorbitol and 28% gly-
cerol). Frozen samples were transported to the Instituto
Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil for
further studies.
DNA preparation
Blood samples were thawed, and 1 ml was used for
DNA extraction with the QIAamp midi kit, as described
by the manufacturer (Qiagen). Samples were resus-
pended in a final volume of 50 μl.
Nested PCRs for pfdhfr and pfdhps
The pfdhfr and pfdhps amplification protocols were as
described elsewhere [18]. Briefly, 2 μlo fD N As o l u t i o n
was added to a 48 μl mixture containing 0.25 μMp r i -
mers M1 (5’ TTT ATG ATG GAA CAA GTC TGC 3’)
and M7 (5’ CTA GTA TAT ACA TCG CTA ACA 3’)
for pfdhfr or primers N1 (5’ GAT TCT TTT TCA GAT
GGA GG 3’)a n dN 2( 5 ’ TTC CTC ATG TAA TTC
ATC TGA 3’)f o rpfdhps. In the nested PCR, 2 μlo ft h e
initial PCR product was mixed with 0.25 μMp r i m e r s
M3b (5’ TGA TGG AAC AAG TCT GCG ACG TT 3’)
and M9 (5’ CTG GAA AAA ATA BCAT CAC ATT
CAT ATG 3’)f o rpfdhfr or primers R2 (5’ AAC CTA
AAC GTG CTG TTC AA 3’) and R (5’ AAT TGT GTG
ATT TGT CCA CAA 3’)f o rpfdhps. The pfdhfr primers
amplify a 594 bp fragment comprising the SNPs A16V/
S, C50R, N51I, C59R, S108N, V140L and I164L, and
pfdhps primers amplify a 711 bp region containing SNPs
S436A/F/C, A437G, K540E, A581G and A613T/S. PCR
reactions were run in the GeneAmp PCR System 9700
(Applied Biosystems). Positive (DNA extracted from
blood from patients with known P. falciparum infection)
and negative (no DNA and DNA extracted from indivi-
duals who had never traveled to malaria-endemic areas)
controls were also used in each round of amplification.
PCR analysis and product purification
PCR products were separated by 2% agarose-gel electro-
phoresis. Products were purified through the Wizard SV
Gel and PCR Clean-Up System (Promega), according to
the manufacturer’s instructions.
DNA sequencing
DNA sequencing from forward and reverse strands was
performed using pfdhfr or pfdhps nested PCR primers
plus the purified product according to Big Dye
® Termi-
nator Cycle Sequencing Ready Reaction version 3.1
instructions (Applied Biosystems). Sequences were read
using an ABI PRISM DNA Analyzer 3730 (Applied Bio-
systems) from the Genomic Platform/PDTIS/Fiocruz
[19]. Forward and reverse sequences were analysed
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tor version 7.0.5.2.
Results
Samples were analysed from 66 patients, aged 21 to 30
years, with a diagnosis of acute uncomplicated falci-
parum malaria. Parasitaemia ranged from 500 to
100,000 parasites/μl. The pfdhfr analysis yielded 61
sequences and that for pfdhps 30 sequences. The failure
to satisfactory amplify pfdhps gene in Angolan samples
might be somehow attributed to primer limitations due
to unknown polymorphisms in target sequences.
The most prevalent polymorphisms were pfdhfr 108N
(100%), 51I (93%), 59R (57%) and pfdhps 437G (93%)
(Table 1). In addition, other polymorphisms were
detected, including 50R in the pfdhfr gene (6%) and
540E (10%) and 581G (7%) in the pfdhps gene. No
mutations were found at 16, 140 and 164 codons from
pfdhfr gene. Considering haplotypes, the most prevalent
were CIRN (51%) and CICN (34%) for pfdhfr gene
(codons 50, 51, 59 and 108), and SGKAA (60%) and
AGKAA (23%) for pfdhps gene (codons 436, 437, 540,
581 and 613) (Table 2).
Only one sample presented a mixed infection for
pfdhfr. Wild-type profiles were observed in pfdhps in
two samples: one from Sambizanga and one from
Imgombotas. No significant difference between the pre-
valence of the pfdhfr and pfdhps haplotypes was
observed among the four municipalities.
Discussion
This study documents a recent prevalence of P. falciparum
antifolate resistance mutations in Luanda, the capital of
Angola. It shows high levels of resistance-associated poly-
morphisms in the genes encoding the antifolate target
enzymes pfdhfr and pfdhps, with most parasites containing
4 mutations that have been associated with an intermedi-
ate level of resistance, and 7% of them additionally con-
taining pfdhps 540E and 581G, both of which are
associated with a higher level of resistance [10,20]. These
molecular profiles are indicative of unsatisfactory response
to SP and they are consistent with the results of a clinical
trial in central Angola that showed poor antimalarial effi-
cacy of this drug when it was used for treatment of chil-
dren under five years old with uncomplicated malaria [21]
as well as with the data of previous in vivo studies from
East African countries [22-24].
The results showed a complex mixture of pfdhfr/
pfdhps haplotypes in Luanda as already reported in
other six provinces of Angola [25,26]. The 164L muta-
tion was not disclosed, corroborating the findings of
other nearby African countries [27-29]. The pfdhfr 50R
SNP herein found confers an increased level of resis-
tance to pyrimethamine and this mutation is character-
istic from South-American isolates [30] and, it was
found only once in Africa, when Kenyan isolates were
evaluated [31]. Three polymorphisms that mediate low-
level resistance to SP, pfdhfr 108N, pfdhfr 51I, and
pfdhps 437G, were nearly universal and the pfdhfr 59R
mutation, which is associated with higher-level resis-
tance, was common. Additional polymorphisms were
also seen, notably the pfdhps 540E and 581G mutations
presented in the same sample that have been associated
with a high-level of SP resistance.
Considering these data, it can be predicted that SP
will have inadequate efficacy for the treatment of falci-
parum malaria, and further that it may no longer be
appropriate for IPT in Angola. Indeed, although the
number of samples available for study was limited, the
prevalence of the pfdhps 540E mutation might suggest
that the cut-off level recently declared by the WHO for
abandonment of IPT with SP in infants may be reached
in this country. Unfortunately, no other drug offers sim-
ple, single-dose IPT. Surveillance works should provide
advanced warning of SP failure in Angola.
Table 1 Pfdhfr and pfdhps SNPs prevalence from P.
falciparum parasites from Luanda, Angola.
Gene SNPs Prevalence (%) Gene SNPs Prevalence (%)
pfdhfr
(n = 61)
16V/S 0/61 (0) pfdhps
(n = 30)
436A 7/30 (23)
50R 4/61 (6) 437G 2/30 (93)
51I 57/61 (93) 540E 3/30 (10)
59R 35/61 (57) 581G 2/30 (7)
108N 61/61 (100) 613T/S 0/30 (0)
140L 0/61 (0)
I164L 0/61 (0)
Table 2 Pfdhfr and pfdhps haplotypes of P.falciparum
parasites from Luanda, Angola.
Gene Haplotypes n % Mutated codons
Pfdhfr
(n = 61)
CIRN 31 51 3
CICN 21 34 2
CNRN 46 2
RICN 46 3
CIC N/S 1 2 1 or 2
Pfdhps
(n = 30)
SGKAA 18 60 1
AGKAA 7 23 2
SAKAA 2 7 0
SGEAA 1 3 2
SGEGA2 7 3
Codon positions: pfdhfr C50R, N51I, C59R and S108N, pfdhps S436A/F/C,
A437G, K540E, A581G and A613T/S. The sensitive haplotype is underlined and
the mutated codons are shown in bold characters.
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Since SP is still used for IPT in pregnant women as well
as to treat bacterial infections, in Angola, a continuous
pressure for such mutations selection may limit the
therapeutic life span of this combination. Therefore the
present data apparently argue against the use of this
drug combination in Angola. The data also emphasize
the need for a closer screening of these polymorphisms,
especially pfdhps 540E, along to the testing of other
drugs for chemoprevention of malaria, including IPT in
pregnant women and children, as an urgent priority.
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